In experimental models there is a relationship between vascular endothelial growth factors and tissue factor. Dr. Poggi discussed the antitumour and anticoagulant effects of heparin and new semi-synthetic sulfaminoheparinsulfates in murine models. Registry of Trials Dr. Zacharski provided an update on the registry of trials of coagulation-reactive drugs in cancer. He noted the negative result of ASA on colon cancer in the Physician's Health System. Dr. Angnelli communicated to Dr. Levine information on an ongoing, multi-center Italian trial in which patients undergoing cancer surgery are randomized to dermatan sulfate or standard heparin.
Patients undergo venography at eight days.
Acute Promyelocytic Leukemia Dr. Rickles provided laboratory data from Intergroup Study 0129. A variety of activation markers were measured in 29 patients. These patients did not have increased levels of fibrinolytic activation markers. The messenger for tissue factor dropped by Day 15 and more so in the ATRA group. ATRA increased IL-1 b gene expression.